CONTACT

+91 80 2808 2808

ContactUs.BBL@biocon.com

Press Releases 2017

Biocon Biologics / News – Posts / Press Releases / Press Releases 2017

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

Fri, 29-Dec-2017
Posted by: Biocon Biologics

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2Positive Breast and Gastric Cancers

Fri, 01-Dec-2017
Posted by: Biocon Biologics

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

Fri, 01-Dec-2017
Posted by: Biocon Biologics

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India

Thu, 23-Nov-2017
Posted by: Biocon Biologics

Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore

Thu, 26-Oct-2017
Posted by: Biocon Biologics

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

Wed, 25-Oct-2017
Posted by: Biocon Biologics

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment

Wed, 06-Sep-2017
Posted by: Biocon Biologics

Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore

Thu, 27-Jul-2017
Posted by: Biocon Biologics

FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab

Fri, 14-Jul-2017
Posted by: Biocon Biologics

Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions

Sun, 11-Jun-2017
Posted by: Biocon Biologics

1
2